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G-CSFa b s t r a c t
Analyses of healthy donors of granulocyte colony-stimulating factor (G-CSF) mobilized hematopoietic stem and
progenitor cells (HSPCs) and of patients undergoing autologous stem cell transplantation have suggested that
individuals harboring the CXCL12-A allele mobilize a higher number of CD34 þ HSPCs after G-CSF adminis-
tration. We typed 463 healthy unrelated donors (376 men and 87 women) who had received daily subcuta-
neous injections at a mean dose of 7.36  1.71 mg/kg G-CSF for 5 days for CXCL12 801 G/A using a real-time PCR
assay. Interestingly, the median concentration of mobilized CD34 þ cells on day 5 was almost identical in
donors with the A-allele (79/mL; range,11 to 249/mL) and the G/G-group (82/mL; range,15 to 268/mL). In addition,
the allelic distribution was not different in donors (n ¼ 11) who mobilized less than 20/mL CD34 þ cells. No
difference in the overall yield of CD34 þ cells in the apheresis product and in the number of CD34 þ cells/kg
recipient could be detected between both groups. In a multivariate regression model for the endpoint
CD34þ cells/mL at day 5, only male sex (regression coefﬁcient, 11.5; 95% conﬁdence interval, 1.7 to 21.2, P¼ .021)
and body mass index as continuous variables (regression coefﬁcient, 3.5; 95% conﬁdence interval, 2.5 to 4.5,
P ¼ .0001) but not age, smoking status, or CXCL12 allelic status represented independent variables. Our data
derived from a large well-controlled cohort contradict previous analyses suggesting an association between
CXCL12 allelic status and the yield of CD34 þ HSPC after G-CSF mobilization. Concentration of CD34 þ cells in
the peripheral blood, the most objective parameter, could not be predicted by CXCL12 genotype.
 2013 American Society for Blood and Marrow Transplantation.INTRODUCTION
Peripheral blood stem cells (PBSCs) collected after mobi-
lization with granulocyte colony-stimulating factor (G-CSF)
are themost frequently applied source of hematopoietic stem
and progenitor cells (HSPCs) for allogeneic transplantation.
This preference is mainly due to a faster engraftment of
neutrophils and platelets and to a less invasive procedure not
requiring in-hospital stays or general anesthesia [1].
In approximately 75% of donors, one single leukapheresis
is sufﬁcient to collect the CD34þ cell dose required, whereas
Table 1
Donor Characteristics
N (Median, Range) Percent
Sex
Men 376 81.2
Women 87 18.8
Age, yr
Median (min-max) 33 (18-54)
BMI, kg/m2
Median (min-max) 25.4 (17.7-44.7)
Smoking status
Smokers 187 40.4
Nonsmokers 276 59.6
Daily alcohol intake
Yes 46 10
No 415 90
Missing n ¼ 2
G-CSF
Lenograstim 449 97
Filgrastim 14 3
Separating machines
Cobe Spectra 352 76
Baxter CS 3000 3 1
Fresenius Comtec 108 23
CD34þ/mL peripheral blood on day 5
Median (min-max) 73 (11-268)
CD34 þ absolute  108 (in ﬁrst
leukapheresis product)
Median (min-max) 6.2 (1.28-21.89)
CD34þ/kg recipient  106
Median (min-max) 8.2 (1.3-72.7)
Number of donors with 2 aphereses 34 7.3
Number of poor mobilizers (CD34þ/mL
peripheral blood on day 5 of G-CSF
treatment <20)
11 2.4
Processed volume in L
(ﬁrst leukapheresis)
Median (min-max) 17.6 (9.9-31.2)
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the target cell dose [2]. However, 1% to 5% of healthy
volunteer PBSC donors unexpectedly fail to mobilize a sufﬁ-
cient quantity of CD34 þ cells [3,4].
To prospectively identify donors in whom G-CSF admin-
istrationwill lead to insufﬁcientmobilization of CD34þHSPC,
predictive markers are warranted. Certain donor characteris-
tics are already considered as predictive markers for the efﬁ-
cacy of PBSC mobilization [5-9]. Particularly, sex, age, and
body weight were shown to inﬂuence mobilization potential
[5-7]. However, donors do present without any negative
predictive factor but unexpectedly fail to mobilize the target
cell dose, which suggests so far unknown determinants of
HSPC ampliﬁcation and release after G-CSF. Consequently, it
seems rational to examine the inﬂuence of possible genetic
factors associated with mobilization efﬁcacy.
Themobilization of PBSC is a complex process, inwhich the
activation of metalloproteases, cellular components, chemo-
kinetactic gradients of CXCL12 and spingosine-1-phosphate,
and b-adrenergic sympathetic nerves are involved [10]. The
interaction between the chemokine CXCL12 (formerly stromal
cellederived factor 1, SDF1) and its receptor CXCR4 have been
described as playing a pivotal role in G-CSFeinduced mobili-
zation of CD34 þ progenitor cells from bone marrow into
peripheral blood [11].
Winkler et al. [12] revealed a G/ A transition at position
801 in the 30-untranslated region (30-UTR) of the CXCL12
gene, suggesting a genetic inﬂuence on the CXCL12eCXCR4
axis. In the homozygous state, SDF1-30A allele delays the
onset of acquired immunodeﬁciency syndrome in late stage
of human immunodeﬁciency virus type 1 infection [12].
Benboubker et al. [13] were the ﬁrst to demonstrate
a signiﬁcant inﬂuence of the CXCL12-30A allele on HSPC
mobilization. In addition, genetic variants of VCAM1 and
CD44, molecules involved in adhesive and chemotactic
interactions of CD34 þ cells within the bone marrow niche,
have been associated with the efﬁcacy of progenitor cell
mobilization [14].
The aim of our study was to investigate the assumed
association of the CXCL12 gene polymorphism and progen-
itor cell mobilization after G-CSF administration in a larger
cohort of unrelated healthy volunteer donors in a retrospec-
tive multicenter study. This setting was not biased by back-
ground disease or chemotherapy.
METHODS
Donor Characteristics
The CXCL12-30-UTR-801-G-A polymorphism, as well as the CD34 þ cell
count/mL peripheral blood on day 5 of G-CSF treatment, CD34þ absolute cell
count in the ﬁrst leukapheresis product, and CD34þ cells/kg recipient, were
analyzed in 463 healthy volunteer donors of allogeneic transplants in an
unrelated setting. PBSC collections were performed at 8 different centers in
Germany. Informed consent was obtained from all 463 donors studied. This
study was approved by the local Ethics Committee in accordance with the
Declaration of Helsinki.
Clinical data were collected retrospectively. DNA samples had been
stored at the repository of the DKMS (German Bone Marrow Donor Center)
after obtaining informed consent. The current analysis was approved by the
Institutional Review Board of the University Hospital Dresden.
Mobilization and Collection of CD34 þ Cells
Most donors (97%) received G-CSF (lenograstim; mean, 7.36  1.71 mg/
kg/d) for 5 days. Within speciﬁc protocols, 3% of the donors received ﬁl-
grastim (10 mg/kg/d). The ﬁrst leukapheresis was performed on day 5. If the
required number of CD 34 þ cells per recipient body weight was not
collected, rhG-CSF administration was repeated (depending on the donor’s
leukocyte count) and a second PBSC collection was performed on day 6.
Administration of rhG-CSF was performed either daily by the donor’s
family doctor (15.3%) or by the donor or a family member every 12 hours(81.9%). PBSCs were collected by different continuous-ﬂow blood cell
separators (Table 1) via bilateral (forearm) peripheral venous access,
whenever possible, or otherwise via a central line in the femoral vein. In
donors who needed a central line, only 1 leukapheresis was performed and
the venous line was removed immediately thereafter. During the ﬁrst leu-
kapheresis, the donor’s total blood volume was processed 4 to 5 times at 50
to 110 mL/min over 3 to 4.5 hours.
Anticoagulationwas performed with ACD-A (ratio, 1:12 to 20), and most
donors received heparin (5000 U per donor). During the second leukaphe-
resis, if necessary, the maximum volume processed was 3 times the donor’s
blood volume, and heparin was used only if the platelet count was
>100  109/L. The desired yield of CD34 þ cells was 4 to 10  106/kg of
recipient body weight, depending on the disease and treatment protocol.
Two leukapheresis procedures were performed in 34 donors (7.3%).Flow Cytometric CD34 Measurement
CD34 cells in peripheral blood and apheresis samples were quantiﬁed by
ﬂow cytometry. Participating centers used either single- or dual-platform
technologies. Measurements of CD34 þ cells and analysis procedure thus fol-
lowed published guidelines [15]. All laboratories had successfully participated
in trans-European interlaboratory tests focusing on the accuracy of CD34 þ
progenitor cell enumeration and had been licensed by national authorities.Analysis of the CXCL12 30-UTR Polymorphism
Genotyping of the CXCL12-30-UTR Single Nucleotide Polymorphism
(SNP) (rs1801157) was performed based on a commercially available, allele-
speciﬁc real-time PCR assay (Invitrogen Assays on Demand, Darmstadt,
Germany) using VIC- and 6-carboxyﬂuprescein (FAM)-labeled speciﬁc
probes for both allelic variants. Brieﬂy, 15 ng genomic DNAwas ampliﬁed in
a Roche Lightcycler 480 using the TaqMan Universal Master mix (Life
Technologies; Darmstadt, Germany). Reaction conditions and cycle param-
eters were chosen as recommended by the manufacturer. Results of auto-
mated allele calling were veriﬁed in a subgroup of 64 patients using an
Msp1-based RFLP assay with primers described byWinkler et al. [12] as well
as with direct sequencing.
Table 2
CXCL12 Genotype Distribution
Genotype CXCL12 Total
GG GA AA
Sex
Men
Count (%) 254 (67.6) 111 (29.5) 11 (2.9) 376 (100)
Women
Count (%) 61 (70.1) 22 (25.3) 4 (4.6) 87 (100)
Total
Count (%) 315 (68) 133 (28.7) 15 (3.2) 463 (100)
Genotype frequencies within the studied population are shown. Fifteen
(3.2%) were genotyped as AA homozygotes, 133 (28.7%) as AG heterozy-
gotes, and 315 (68%) as GG homozygotes. No signiﬁcant difference could be
detected in the distribution of GG/GA/AA genotypes in the examined pop-
ulation. One hundred forty-eight donors (32%) were CXCL12-30A allele
carriers and 315 (68%) were genotyped as GG homozygotes. No signiﬁcant
difference among the CXCL12-30A allele carriers compared with GG
homozygotes could be detected.
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Statistical analysis was performed using SPSS software (SPSS 19.0 for
Windows; SPSS Inc., Chicago, IL). The primary endpoint inﬂuence of CXCL12-
30-UTR-801-G-A polymorphism on CD34 þ cell count/mL peripheral blood
on day 5 of G-CSF treatment was tested by applying a linear model with
adjusting covariables for age, sex, body mass index (BMI), and smoking
status. The signiﬁcance level was set to P¼ .05. This analysis is considered to
be conﬁrmatory.
For continuous variables, means and standard deviations are presented.
Differences ofmeans in univariate analyses have beenanalyzedwith the t-test
for independent samples or the paired t-test when examining the inﬂuence of
G-CSF treatment on blood counts before and after G-CSF administration.
For categorical variables, absolute and relative frequencies are presented
and compared with uncorrected chi-square tests. These analyses are
considered explorative. The signiﬁcance level is set to P ¼ .05 for each test.
No adjustment for multiple tests was performed.RESULTS
Donor Characteristics
Donor characteristics are summarized in Table 1. In our
examinedpopulation, 81.2%of thedonorsweremenand18.8%
were women. The median age was 33 years (range, 18 to 54).
ThemeanCD34þ cell count/mLperipheral bloodonday5ofG-
CSF treatment was 81.06  44 (minimum 11, maximum 268).Allele Frequencies for CXCL12-30 A and G Within the
Population Studied
Within the 463 donors studied, we identiﬁed 15 as AA
homozygotes (3%), 133 as AG heterozygotes (29%), and the
majority of 315 donors (68%) as GG homozygotes (Table 2).Figure 1. CD34 þ cell counts/mL peripheral blood on day 5 of G-CSF treatment in cor
higher cell doses compared with female, lightweight donors. Association of CD34 þ ce
(C) Lack of inﬂuence of the CXCL12 genotype on the CD34 þ cell count/mL peripheraTaken together, 148 donors (32%) were CXCL12-30A allele
carriers compared with 315 GG homozygotes.
In our examined population, no signiﬁcant difference
could be detected in the distribution of GG/GA/AA genotypes
within the male or the female donors (67.6% of men and
70.1% of womenwere genotyped as GG homozygotes; 2.9% of
men and 4.6% of women were detected as AA homozygotes).
Also, no signiﬁcant difference could be demonstrated among
the CXCL12-30A allele carriers compared with GG homozy-
gotes (32.4% of male donors and 29.9% of female donors were
genotyped with 1 or 2 CXCL12-30A alleles).
Hardy-Weinberg Equilibrium
The allele frequencies were calculated .82 for the G0
allele and .18 for the A0 allele. The expected genotype
frequencies were therefore identiﬁed as .68 (E(GG)), .29
(E(GA)), and .03 (E(AA)), whereas the expected genotype
counts within our population of 463 were examined as
314.34 for E(GG), 134.31 for E(GA), and 14.35 for E(AA). We
found no signiﬁcant deviation from the Hardy-Weinberg
equilibrium, illustrating that this cohort was big enough
to reﬂect expected genotype frequencies. Therefore, it can
be assumed that effects such as inbreeding, mutation, gene
ﬂow, genetic drift, or nonrandom mating leading to devi-
ation from Hardy-Weinberg equilibrium do not apply in
this setting.
CD34 þ HSPC on Day 5 in the Peripheral Blood (Primary
Endpoint)
As primary endpoint of this study, we examined the
inﬂuence of the CXCL12-30A allele on the CD34 þ cell count/
mL peripheral blood on day 5 of G-CSF treatment as a poten-
tial predictive marker for PBSC mobilization in a linear
model. In our study, the CXCL12-30A allele was not associated
with good mobilization efﬁcacy, indicated by an adjusted
estimate for the difference of 2.46 CD34þ cells/mL peripheral
blood (95% conﬁdence interval, 5.66 to 10.58, P ¼ .552).
Besides the factor “presence of CXCL12-30A allele (yes/
no),” this adjustedmodel included the independent variables
age, sex, smoking status, and BMI. This analysis indicates that
both sex (P ¼ .021, Figure 1A) and BMI (P < .001, Figure 1B)
are statistically signiﬁcant predictors, whereas CXCL12-30A
allele, smoking status, and age are not. In the linear regres-
sion model, the CD34 þ count/mL peripheral blood in men
was 11.5 cells higher compared with women.With every BMI
point as a continuous variable, the CD34 þ cell count/mL
peripheral blood raises by 3.5 cells/mL. The presence of therelation to sex (A) and BMI (B), suggesting male donors with high BMI obtain
lls/mL peripheral blood with sex and BMI was veriﬁed in multivariate analysis.
l blood on day 5 of G-CSF treatment.
Table 3
CXCL12 Genotype Distribution Within Poor Mobilizers
Genotype CXCL12
GG GA or AA Total
CD34 þ cell count/mL peripheral
blood on day 5 of G-CSF
treatment
>20/mL
Count (%) 307 (67.9) 145 (32.1) 452 (100)
20/mL
Count (%) 8 (72.7) 3 (27.3) 11 (100)
Total
Count (%) 315 (68) 148 (32) 463 (100)
Genotype distributions among normal (>20 CD34þ/mL peripheral blood)
and poor (20 CD34þ/mL peripheral blood) mobilizers are shown. No
signiﬁcant differences in the distribution of GG homozygotes within the
poor mobilizer group compared with the normal mobilizer group could be
detected.
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cell mobilization. With this analysis, approximately 11% of
variance can be explained, suggesting other factors inﬂu-
encing the CD34 þ cell count/mL peripheral blood on day 5 of
G-CSF treatment not considered in this setting. When GG
homozygotes (mean, 81.9  45.9) were compared with AA
homozygotes (83.5  61) in a sensitivity analysis, no signif-
icant inﬂuence on CD34 þ cell count/mL peripheral blood
could be observed (Figure 1C).
Total Yield of CD34 þ HSPC in the First Leukapheresis
Product and CD34 þ Cells/kg Recipient
The above-mentioned multivariate model was also
applied as exploratory analysis examining whether the
CXCL12-30A allele is an independent inﬂuencing factor on the
total yield of CD34 þ HSPC in the ﬁrst leukapheresis product
and the CD34 þ cell count/kg recipient. Again, the analysis
indicates that both BMI (P < .001) and sex (P < .001) are
statistically signiﬁcant factors, whereas CXCL12-30A allele,
smoking status and age are not.
When GG homozygotes (mean, 9.6  6.3) were compared
with AA homozygotes (mean, 9.5  6.7), no signiﬁcant
inﬂuence on CD34 þ cells/kg recipient could be observed.
When GG homozygotes (mean, 6.6  3.2) were compared
with AA homozygotes (mean, 6.3  4.0), no signiﬁcant
inﬂuence on CD34 þ HSPC in the ﬁrst leukapheresis product
could be seen.
Poor Mobilizers with <20 CD34 þ Cells/mL
The donors were divided into 2 groups (poor mobilizers
and normal mobilizers, Table 3) based on the clinically
relevant cut-off value of 20 CD34 þ cells/mL peripheral blood
on day 5 of G-CSF treatment. According to this deﬁnition, 11
donors were poor mobilizers (9 men and 2 women). Eight of
the poor mobilizers (72.7%) were GG homozygotes, whereas
67.9% of the normal mobilizers were GG homozygotes. We
found no signiﬁcant differences in the distribution of GG
homozygotes within the poor mobilizers compared with the
normal mobilizers group.
The 2 mobilizer groups did not differ concerning smoking
status, daily alcohol intake, BMI, or G-CSF doses. However,
the poor mobilizer group was associated with lower age,
lower lactate dehydrogenase, and lymphocytes in peripheral
blood at day 5 of G-CSF treatment.
Second Leukapheresis Needed to Obtain the Target Cell
Dose
Thirty-four of 463 donors (7.3%) needed a second leuka-
pheresis the following day to obtain the target cell dose. The
distribution of sex signiﬁcantly differed in these 2 groups.
Only 5.3% of male donors but 16.1% of the female donors
needed a second apheresis (P ¼ .001, data not shown).
No signiﬁcant differences in distribution of GG/GA/AA
genotypes within the 2 groups could be observed. The BMI
was signiﬁcantly lower in the 2-aphereses group (mean,
23.4  2.5) compared with the 1-apheresis group (mean,
26.1  3.9; P < .001). Both hemoglobin (P ¼ .001) and
hematocrit (P ¼ .001) at the preliminary examination were
signiﬁcantly lower in the 2-aphereses group due to the
higher percentage of women. Because of the same reason,
lactate dehydrogenase (P < .001), leukocytes (P ¼ .006), and
hemoglobin (P ¼ .023) at day 5 of G-CSF treatment were also
signiﬁcantly lower in the 2-aphereses group compared with
the 1-apheresis group. Interestingly, only 9 of the 34 donors
(26.5%) in need of a second apheresis yielded a CD34 þ cellcount <20/mL peripheral blood at day 5 of G-CSF treatment
and were therefore considered poor mobilizers.DISCUSSION
Within this study, we investigated the previously re-
ported association of the CXCL12 gene 30-UTR polymorphism
and hematopoietic progenitor cell mobilization after G-CSF
administration in a large cohort of 463 healthy volunteer
donors for unrelated recipients. In multivariate analysis, BMI
and sex were the only signiﬁcant factors that inﬂuenced
CD34 þ cell count/mL peripheral blood on day 5, the
CD34þ absolute cell count in the ﬁrst leukapheresis product,
and the number of CD34 þ cells/kg recipient. In our exam-
ined population, the presence of the CXCL12-30A allele was
not signiﬁcantly associated with mobilization efﬁcacy in the
multivariate model.
Available information on predictive markers for stem cell
mobilization by G-CSF are inconsistent, and predictive
factors vary from one study to another due to heterogeneous
populations of autologous and allogeneic donations and
small sample size [5-9,16]. In contrast to our ﬁndings,
Bogunia-Kubik et al. [17] implied that the frequency and
number of CD34 þ progenitor cells in the ﬁrst leukapheresis
product were signiﬁcantly higher in donors with the
CXCL12-30A allele compared with GG homozygotes in
a cohort of 65 healthy donors. Moreover, these data sug-
gested that more leukaphereses were needed to obtain the
required number of CD34 þ HSPCs for transplantation from
CXCL12-30 GG homozygous donors compared with the
CXCL12-30A carriers. Male sex was associated with lower A
allele frequencies, whereas allele frequencies where not
inﬂuenced by sex in our population.
When dividing the donor cohort into a poor versus
a normal mobilizer group by the clinically relevant cut-off
value of 20 CD34 þ cells/mL peripheral blood, 9 of 11 poor
mobilizers (81.8%) were men, which reﬂects our examined
overall populationwith 81.2% men. No signiﬁcant differences
in GG/AG/AA genotype distribution between the poor and
normal mobilizer groups were detected in our population.
However, the poor mobilizer group in our study was asso-
ciated with younger age and low peripheral blood counts
before the ﬁrst apheresis. The allele frequencies were
calculated .82 for G0 allele and .18 for A0 allele, which
resembles a distribution previously described in other
studies [12,18]. Interestingly, Benboubker et al. [13] found
a signiﬁcant difference in genotype distribution in their
J. Lenk et al. / Biol Blood Marrow Transplant 19 (2013) 1514e1529 1521cohort between poor and good mobilizers that can possibly
be explained by the smaller sample size, the autologous
setting in their study, and a different cut-off value.
Thirty-four donors in our population needed a second
apheresis to obtain the target cell dose. This group was
associated with female sex, lower BMI, and lower blood
counts, suggesting these variables as primary markers for
poormobilization capacity. Approximately only one fourth of
donors in need of a second leukapheresis yielded <20
CD34 þ cells/mL peripheral blood and were therefore con-
sidered to be poor mobilizers, suggesting a second leuka-
pheresis was not a good predictor for poor mobilization
capacity. Contrary to the ﬁndings of Ben Nasr et al. [3], no
difference in GG/AG/AA genotype distribution was detected
in the 2-aphereses group compared with the 1-apheresis
group, probably due to a different ethnical background and
partially because of the autologous setting of their cohort.
Our data derived from a large, well-controlled cohort
contradict previous analyses suggesting an association
between CXCL12 allelic status and the yield of CD34þHSPCs.
Concentration of CD34 þ HSPCs in the peripheral blood, the
most objective parameter, could not be predicted by CXCL12
genotype. As the content of CD34 þ HSPCs in the graft is an
important parameter for transplant outcome, more com-
prehensive genome-wide association studies in larger donor
cohorts are warranted to identify other potential genetic
predictors for stem cell mobilization.
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